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ABSTRACT 
 
Sudden sensorineural hearing loss (SSHL) is characterized by abrupt, mostly 
unilateral loss of hearing, frequently associated to aural fullness, tinnitus and vertigo. It 
affects 5-20/100.000 people/year (particularly working adults in the 40
ths
), with huge 
impact on quality of life. Possible causes include infectious, circulatory, traumatic, 
immunologic, metabolic, neoplastic, neurologic, toxic and unidentified cochlear 
diseases. Nevertheless, SSHL’s etiology remains unknown in most cases (80%), giving 
rise to controversial (and frequently ineffective) treatments. Available therapies range 
from corticosteroids to antivirals, vasodilators, antiaggregants, anticoagulants, vitamins 
and hyperbaric oxygen (HBO).  
Given the lack of data concerning SSHL’s etiology and physiopathology, we 
intend to evaluate clinical evolution of such patients treated with HBO in the 
Underwater and Hyperbaric Medical Center (UHMC) at Lisbon from 2000 to 2005 
during a minimum period of 5 years, in an attempt to identify eventual risk factors or 
clinical associations to SSHL.  
The intended retrospective study is based on the review of patients’ medical 
charts from UHMC and confidential follow-up questionnaires applied telephonically 
both to patients (study group) and patients’ spouse/partner/close family member 
(control group), focusing past and present medical history.  
A preliminary study of 20 subjects (10 of each group) was performed to 
anticipate difficulties and to estimate the required logistics. The identified difficulties 
were: 1) selection of subjects with valid phone numbers and complete medical charts 
(with initial and final audiograms); 2) telephonic contact with subjects from the study 
and control group; 3) human logistics required. 
As it is believed that SSHL is not a disease by itself but rather a symptom of an 
underlying disease, we believe that this epidemiologic study is important and will 
hopefully generate sound scientific knowledge concerning physiopathology and 
mechanism of disease of SSHL.  
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RESUMO 
 
A surdez súbita (SS) caracteriza-se por uma perda abrupta de audição, mais 
frequentemente unilateral e associada a sensação de preenchimento aural, acufenos e 
vertigem. Afecta 5-20/100.000pessoas/ano (sobretudo adultos em fase activa na década 
de 40), com grande impacto na qualidade de vida. Possíveis causas incluem doenças 
infecciosas, circulatórias, traumáticas, imunológicas, neoplásicas, neurológicas, 
tóxicas e cocleares. No entanto, a causa da SS permanece desconhecida na maioria dos 
casos (80%), o que origina tratamentos controversos e frequentemente ineficientes. Os 
tratamentos disponíveis variam desde corticosteróides a antivirais, vasodilatadores, 
anti-agregantes, anticoagulantes, vitaminas e oxigénio hiperbárico (OHB). 
Atendendo a falta de informação relativa à etiologia e fisiopatologia da SS, 
pretendemos avaliar a evolução clínica dos doentes com SS tratados com OHB no 
Centro de Medicina Subaquática e Hiperbárica (CMSH) de Lisboa entre 2000 e 2005, 
durante um período mínimo de 5 anos, na tentativa de identificar eventuais factores de 
risco ou noxas clínicas com a SS. 
O estudo retrospectivo proposto baseia-se na revisão de processos clínicos do 
CMSH e na aplicação telefónica de questionários médicos de “follow-up” 
confidenciais – tanto a doentes (grupo de estudo), como aos respectivos 
esposos/companheiros/membros próximos da família (grupo de controlo) –, com 
particular ênfase nos antecedentes médicos e história clínica actual. 
Um estudo preliminar de 20 pessoas (10 doentes e 10 controlos) foi efectuado 
para antecipar dificuldades e estimar as necessidades logísticas. As dificuldades 
identificadas foram: 1) selecção dos doentes com números de telefone válidos e 
processos clínicos completos (com audiograma inicial e final); 2) contacto telefónico 
com os participantes de ambos os grupos (de estudo e controlo); 3) recursos humanos 
requeridos.  
Dado que a SS não é uma doença em si, mas um sintoma de uma doença 
subjacente, acreditamos que este estudo epidemiológico seja importante e útil, capaz de 
gerar novas luzes sobre a fisiopatologia e mecanismos desta entidade clínica. 
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INTRODUCTION 
Sudden Sensorineural Hearing Loss 
 
Sudden sensorineural hearing loss (SSHL) is characterized by new onset of 
unilateral or bilateral sensorineural hearing loss that occurs within minutes or hours. It 
is defined by the US National Institute for Deafness and Communication Disorders 
(NIDCD) as an idiopathic loss of hearing of at least 30 decibels (dB) affecting at least 3 
consecutive frequencies occurring within 3 days (compared to the opposite ear’s 
thresholds)
1
. The term “idiopathic” is applied when no known cause is identified despite 
adequate investigation (including clinical, laboratory and imaging tests) – which 
happens in 85-90% of the cases
2
. 
Estimates of the overall incidence of SSHL range from 5 to 20 per 100.000 
persons per year
2
, affecting particularly working adults in the 40
ths
, with equal sex 
distribution. It is likely though that its incidence is increasing and also underestimated 
due to a high rate of spontaneous remission or recovery
3-5
.  
This relatively common otologic condition owns its special place in the 
otolaryngology literature due to its unclear etiology and its consequently controversial 
(and frequently ineffective) treatment. Despite its 1
st
 early description, in 1944 (De 
Klein)
6
, the entity is still poorly understood and significant uncertainty subsists among 
otolaryngologists concerning the choice of what seems to be the more effective 
treatment regimen.  
 
 
Pathophysiology 
 
SSHL is believed to occur as a direct damage to the cochlea, auditory nerve or, 
less frequently, higher aspects of central auditory perception or processing. Four main 
theories have been proposed to explain its mechanisms: 
1. Viral  
The evidence that implicate viral infection as one of the cause of SSHL is rather 
circumstantial and based on a moderate prevalence of recent viral-type illness in 
patients who present with SSHL (17-33% – a prevalence that is similarly identified in 
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patients visiting their otolaryngologist without hearing loss). According to this theory, 
viral infection of the cochlea or the cochlear nerve and/or reactivation of a neutropic 
virus (such as herpesvirus) in the internal ear would be responsive for the hearing 
loss
5,7-8
. This theory is supported by higher rates of seroconversion for the herpesvirus 
family found in the population of patients with sudden hearing loss, and cochlear 
damages consistent with viral injuries found in temporal bone histopathologic studies of 
such patients
9-10
. Another supportive fact to the viral theory is the seasonal pattern of 
SSHL’s occurrence: higher in April and October, compatible with seasonal peaks of 
infection with rhinovirus (April, October), influenza, measles, rubella and respiratory 
syncytial’ viruses (March-May). In addition, 30 to 40% of the patients that experience 
SSHL relate acute respiratory infection in the precedent week. 
Neverheless, the identified patterns of cochlear damage (loss of hair cells and 
supporting cells, atrophy of the tectorial membrane and the stria vascularis, and 
neuronal loss) can also be observed in other pathologies, and no virus, viral antigens or 
RNA/DNA was ever identified in the inner ear during histopathologic studies.
8
 
 
2. Vascular 
The cochlea is an end organ with respect to its blood supply, with no collateral 
vasculature. Vascular compromise of the cochlea due to thrombosis, embolus, reduced 
blood flow, or vasospasm of the arteria labyrinthi seems to be a likely etiology for 
SSHL, with the occurrence of severe damage to cochlear sensory cells
5,7-8,11-12
. The time 
of course correlates well with a vascular event, a sudden or abrupt loss. Moreover, cell 
death would not occur until a critically low oxygen partial pressure would be attained, 
which could relate to reversible hearing loss in cases where blood supply would be 
interrupted for short periods of time (less than 1h)
12
. However, this theory implies that 
patients presenting with SSHL would have higher rates of cardiovascular risk factors 
(such as advanced age, dyslipidemia, thromboembolic diseases, hyperviscosity 
syndromes, diabetes) than patients with no SSHL, which is not observed. 
 
3. Intracochlear membrane rupture 
Thin membranes separate the inner ear from the middle ear, and within the 
cochlea, delicate membranes separate the perilymphatic and endolymphatic spaces. 
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Rupture of either or both sets of membranes may occur in cases of craniofacial trauma 
(with middle and inner hear injury), heavy weight lifting and intracranial pressure rise, 
and may theoretically be responsible for a sensory hearing loss. A leak of perilymph 
fluid into the middle ear via the round window or oval window has been postulated to 
produce hearing loss by creating a state of relative endolymphatic hydrops or by 
producing intracochlear membrane breaks, which would allow mixing of perilymph and 
endolymph, effectively altering the endocochlear potential
5,7-8
. Histologic evidence has 
been documented by Gussen
13
.  
 
4. Immune-mediated inner ear disease 
Cochlear inflammation may be secondary to autoimmune etiologies, with cochlear 
and/or retrocochlear damage provoked by activated T cells, resultant from infectious 
diseases or circulating autoantibodies.  The association of hearing loss in Cogan 
syndrome, systemic lupus erythematosus, polyarteritis nodosa, Buerger’s disease and 
other autoimmune rheumatologic disorders has been well documented
5,7-8
. Progressive 
sensorineural hearing loss is observed in those cases, but eventual link to SSHL is a 
strong possibility. The existence of multiple immune-mediated disorders and 
autoantibodies (against inner ear proteins such as choline transporter-like protein 2, 
collagen type 2, β-actine, coclein, β-tectorine) has been identified by recent studies in 
patients with SSHL
14-18
. With better markers for inner ear autoimmunity, perhaps a 
greater linkage with SSHL will be found. Questions about an eventual link between the 
time of occurence of SSHL and the development of an autoimmune disease remain – at 
what point of disease progression is expected SSHL to happen? May it be its first 
symptom?   
 
A disease process involving any of these theoretical possibilities could have 
sudden hearing loss as a symptom. Unfortunately, none of these theories explains the 
entity by itself, pointing instead to a multifactorial etiology. Localized vascular lesion 
could be induced, for example, by autoantibodies generated from cross-linked reaction 
to viral antigens in the inner ear. The unilateral occurence of SSHL in the vast majority 
of cases remains also a mystery, poorly explained by current hypotheses.  
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More recently, neoplastic, metabolic, neurologic and toxic etiologies were also 
identified
19
 as a potential cause of SSHL, with no further success in clarifying this 
condition.  
 
 
Diagnosis 
 
Clinical features of SSHL are very characteristics: a sudden hearing loss, 
generally unilateral, associated to tinnitus in 70% of the cases and aural fullness. 
Vertigo is reported in as much as 50% of the patients, varying from mild instability to 
severe vertigo
5,7
. The overall audiological burden of SSHL is considerable: difficulty 
with conversation and hearing in noisy environments, and inability to locate the origin 
of sound (with related frustration and disorientation, and possible danger, with higher 
risk for accidents)
19
. Nevertheless, and most of the times, the most impairing symptoms 
are the accompanying tinnitus (sometimes so severe that it can disrupt sleep and the 
ability to concentrate at work or in social interactions, with subsequent depression, 
irritability, frustration, stress and feelings of helplessness) and vertigo (which may vary 
from a mild and supportable unbalance to a severe loss of spatial references and 
inability to function). Specific clinical questionnaires – Tinnitus Handicap Inventory 
(THI)
20
 and Dizziness Handicap Inventory (DHI)
21
 – were developed to assess 
functional, emotional and social impact of such symptoms (Annex 1). As a brief, easily 
administered self-report questionnaire, these inventories are extremely useful not only 
as a simple mean to evaluate the disabling consequences of tinnitus and dizziness, but 
also as a qualitative and quantitative measure of initial and post-treatment handicap. 
SSHL is considered an otologic emergency. Early presentation to a physician 
and early institution of treatment improves the prognosis for recovery. The immediate 
goal is discovering a treatable or defined cause of the sudden hearing loss. Information 
about the onset, time course, associated symptoms, circumstance of occurrence, past 
medical history and previous and current medication is crucial. Physical examination, 
focusing otologic and neurologic inspection, and audiometric tests are essential. 
Additional testing, such as magnetic resonance imaging, is also important to exclude 
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treatable diseases (for example vestibular schwannoma, central nervous system 
malignancies, stroke or degenerative illnesses). 
 
 
Treatment 
 
Treatment of SSHL remains controversial among otologists. Available therapies 
are varied, administered on either an inpatient or outpatient basis, and in different 
pharmacological doses and schemes. This diversity reflects both the different etiologies 
that may cause sudden hearing loss and the uncertainty in diagnosis. They range from: 
- Antiviral agents: acyclovir and valacyclovir have been used to treat a 
presumed viral etiology of SSHL
5,7
. An important limitation is their 
effectiveness, only useful against herpesvirus family, and in the 1
st
 48-72h of 
infection. 
- Vasodilators: in theory, vasodilators improve the blood supply to the 
cochlea, reversing hypoxia. In general, these agents have effects on the 
systemic vasculature
5,7
. Examples of agents used in the past: carbogen, 
procaine, niacin, papaverine. 
- Rheologic agents: by altering blood viscosity, these agents seek to ameliorate 
oxygen delivery to peripheral tissues
22-24
. Dextrans (plasma expansors) cause 
hypervolemic hemodilution and affect factor VIII, improving by two ways 
blood flow. Pentoxifylline does that by affecting platelet deformability. 
Anticoagulants (heparin, warfarin) interfere with the coagulation cascade, 
avoiding thrombi and emboli. 
- Vitamins and mineral salts: vitamin A, B and E have been used based on 
their rheologic and antioxidant properties (beneficial in ischemic tissues). 
Magnesium, with its important role in cellular membranes’ permeability and 
polarization, and in cellular metabolism, has been reported to be useful in 
recovery from hearing loss related to sonotrauma and ototoxicity
25
. 
Inferences were made concerning its probable effectiveness in patients with 
SSHL
26
. 
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- Corticosteroids: oral corticosteroid therapy is one of the few modalities that 
have proved to be effective in randomized controlled studies
19,27-28
, probably 
due to its anti-inflammatory and immunosuppressive effects, also verified in 
the cochlea and auditory nerve. However, it is related to significant systemic 
adverse effects and the alternative (intratympanic steroid therapy) is still 
under study
 29-33
.  
- Hyperbaric oxygen (HBO): as a primary, adjunct or secondary therapy, it 
appears to be a valid choice
7,19,34-35
, especially where systemic steroids are 
contraindicated or in patients who failed to respond to such drugs, with the 
benefit of less adverse effects. Its mechanism of action will be discussed in 
the next chapter. 
 
Recent guidelines from the American Academy of Otolaryngology resume the 
current knowledge and only recommend for the treatment of SSHL, as an “option” 
(evidence grade D), the use of systemic corticoterapy (intratympanic delivery may be 
considered in selected cases) and/or HBO, initiated in the 1
st
 6 weeks or 3 months of 
occurrence of SSHL, respectively
19
. Real effectiveness of such treatments remains 
unclear, partly due to the lack of double-blind randomized controlled studies (case of 
HBO), and partly due to the high rate of spontaneous remission or recovery, which 
tends to occur between the first 2 weeks and 6 months of the onset of the hearing loss 
(therefore coincident with the beginning of treatments). 
 
 
Prognosis 
 
As referred above, the spontaneous recovery rates for SSHL are generally good, 
ranging from 47-63% in the published literature (with the caveat that different studies 
used different criteria for degrees of recovery)
2-5
. Selection bias is likely to affect most 
studies of SSHL because patients with sudden hearing loss and spontaneous recovery 
within a few days probably do not seek medical evaluation. By opposition, many studies 
showing high recovery rates are based on questionable criteria of recovery, which may 
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erroneously raise estimations. The true spontaneous recovery rate is therefore unknown, 
but efforts are being made to gather reliable data.  
The same happens with the estimated rates of recovery of the remaining 37%-
43% patients with no spontaneous recovery submitted to treatment for SSHL. Estimated 
rates of total and partial recovery rates with current treatment regimens are as low as 18-
25% and 40-60% respectively
3-5
, but true values will only be known after 
standardization of recovery criteria. 
To address this issue, the American Academy of Otolaryngology proposes in its 
recent guidelines about SSHL, the following measures for futures outcomes 
assessment
19
: 
- If no known asymmetry of hearing existed before the onset of SSHL, the 
opposite ear should be the reference against which recovery should be 
compared. 
- Complete recovery requires return to within 10dB of the unaffected ear and 
recovery of word recognition scores to within 5 to 10% of the unaffected ear. 
- Partial recovery is characterized by more than 10dB improvement of the 
hearing level. 
- No recovery is verified when less than 10dB improvement of hearing level 
is achieved. 
 
Negative known prognostic factors include age (younger than 15 years or older 
than 65 years), vertigo at the onset, severe hearing loss (superior to 50dB of hearing 
level); audiometric pattern with plain curve or high-frequency loss, and therapeutic 
delay (superior to 7-14 days)
2-3,7-8,36
. Recurrence is estimated to happen in only 2-5% of 
the cases, but long-term follow-up of patients with SSHL is required to ensure that 
SSHL that no treatable disease manifests over time, having SSHL as its first symptom 
(malignancies, auto-immune diseases, degenerative or cardiovascular pathology and 
others). 
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Hyperbaric Oxygen 
 
Hyperbaric oxygen (HBO) is based on the delivery of pure (100%) oxygen to 
patients at pressures that are 2-3 times higher than sea level atmospheric pressure. The 
patients are kept inside a hyperbaric chamber (Annex 1) during 90 minutes and the 
increased pressure they endure (usually 2,5 atmospheres – ATA) aims at enhancing the 
amount of oxygen dissolved in the plasma, thus increasing the arterial partial pressure 
of oxygen and allowing it to reach hypoxic tissues (the cochlea, in this case)
37
.  
 
Biochemical effects of O2 
 
Before reaching the sites of utilization within the cells, the oxygen moves down 
a pressure gradient from inspired to alveolar gas, arterial blood, capillary bed, and 
across the interstitial and intercellular fluid. Under normobaric conditions, the gradient 
of pressure of oxygen (PO2) known as the “oxygen cascade” starts at 21,2 kPa (159 
mmHg) and ends up at 0,5-3 kPa (3,8-22.5 mmHg) depending on the target tissue
7
. The 
arterial oxygen pressure (PaO2) is approximately 95 mmHg and the tissue oxygen 
pressure (PtO2) is approximately 55 mmHg. These values are markedly increased by 
breathing pure oxygen at greater than atmospheric pressure.  
HBO is limited by toxic oxygen effects to a maximum pressure of 300 kPa (3 
ATA). Because partial pressure of carbon dioxide in arterial blood does not vary 
significantly between 100 and 300kPa (1 and 3 ATA), the increased alveolar oxygen in 
hyperbaric condition easily passes the alveolar-capillary space and is diffused into the 
venous pulmonary capillary bed in higher quantities than in normobaric condition, 
accordingly Fick’s laws of diffusion
7 
(Annex 2). 
 
Hyperoxia and hyperoxygenation 
 
Oxygen is transported in the blood by two different systems: chemically, bound 
to hemoglobin, and physically, dissolved in the plasma. During normal breathing in our 
1 ATA environment (at sea level), hemoglobin has an oxygen saturation of 97%, 
representing a total oxygen content of about 19,7mL/100mL of blood (or 19,7vol.%), 
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because 1g of 100% saturated hemoglobin carries 1,34mL of oxygen
38
. In such 
condition, the amount of oxygen dissolved in plasma is 0,285vol.%, performing a total 
of 19,985vol.% of oxygen
38
 (Annex 2).  
The main effect of HBO is hyperoxia. During this therapy, and because further 
oxygen saturation of hemoglobin is impossible beyond 20,1vol.%, the increase of 
arterial oxygen is due to the increase of the dissolved fraction in the plasma. At an 
ambient pressure of 3 ATA and breathing 100% oxygen, the alveolar oxygen pressure is 
approximately 2193mmHg, the PaO2 is at least 2052mmHg and the tissue concentration 
(PtO2) is at least 402,8mmHg
38
. At this partial pressure of oxygen, the dissolved 
fraction of oxygen in plasma is approximately 6vol.% (6mL/100mL of plasma), 
reaching a total volume of oxygen in the circulating blood equal to 26,1vol.%, which is 
more than enough to fulfill basic oxygen metabolic needs
38
 (Annex 2).  
Furthermore, it must be taken into account that hemoglobin is also fully 
saturated on the venous side (which does not happen under normobaric condition), 
which leads to increased PaO2 throughout the entire vascular bed. Since oxygen (and 
other gases) diffusion is driven by a difference in partial pressure across both sides (of 
endothelial or tissue cellular membranes), oxygen will be forced further out of the 
vascular bed into tissues, diffusing to areas normally inaccessible when transported by 
hemoglobin
38
. 
 
 
Physiological and therapeutic effects of O2 
 
In normal tissues, the primary action of oxygen is to cause general 
vasoconstriction (especially in the kidneys, skeletal muscle, brain and skin), without 
decrease of oxygen pressure in the tissues. This hyperoxic vasoconstriction elicits a 
“Robin-Hood effect”: reduction of blood flow to well-oxygenated tissues is not verified 
in previously hypoxic areas, where the microcirculatory blood flow remains unchanged. 
Consequently, oxygen availability to hypoxic tissues is increased and oxygen pressure 
in all tissues is raised to levels close to normal
39
. This hemodynamic and 
microcirculatory effect of HBO appear to be effective in compensating ischemic 
conditions, particularly in cases of heterogeneous microcirculatory hypoperfusion
39
. 
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Another important factor to consider in ischemic tissues is the reperfusion 
injury, also called the “oxygen paradox”. The re-oxigenation phase is characterized by 
vasoconstriction, platelet and polymorphonuclear leukocytes activation, release of 
inflammation mediators and the production of free oxygen radicals. HBO is frequently 
associated with the nefarious production of free radicals but in certain conditions, and 
against one might though, HBO appears to be effective in reducing ischemia-
reperfusion related injury
39-41
. Although evidence of HBO’s benefice in the treatment of 
this issue is increasing, further studies are needed to clarify the complete mechanism by 
which this phenomenon occurs. 
 
The therapeutic actions of HBO are believed to be related not only to the direct 
physical effects of oxygen on blood and tissues but also to a number of secondary 
physiological and biochemical benefits, such as
7,37-40
:  
- Edema reduction: ischemia induces a functional alteration of endothelial 
cells by the loss of their intercellular connection and energy homeostasis. 
Consequently, an increase in permeability of the capillary vessel wall and an 
in plasmatic filtration is observed causing interstitial edema responsible for 
compartment syndrome. The increase in compartmental pressure again 
causes ischemia as compression of blood vessels aggravates the problem of 
tissue hypoxia – a vicious circle. HBO reduces edema both by 
vasoconstriction, and by improved homeostasis mechanisms (such as 
active membrane transport – e.g. sodium-potassium pump – and leukocyte 
adhesion inhibition – with reduced tissue damage and enhanced leukocyte 
motility, thus improving microcirculation).  
- Anti-inflammation: ischemic hypoxia induces an inflammatory reaction and 
activates polymorphonuclear leukocytes (PMN’s) by pro-inflammatory 
mediators, which then adhere to the micro-vascular endothelium by means of 
adhesion molecules (selectins, integrins). PMN’s are required for necrotic 
debris removal after severe ischemia. The cascade of diapedesis is 
orchestered by these adhesion molecules, cytokines and nitric oxide. The 
ensuing tissue damage is no longer limited to free radicals but also by 
proteolytic enzymes released by PMN’s (elastases, collagenases, 
Sudden Sensorineural Hearing Loss – evaluation of co-morbidities and potential clinical associations 
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gelatinases), which demonstrate a much longer activity than free radicals. 
HBO reduces inflammation through leukocyte adhesion inhibition, with 
subsequent decreased release of proteolytic enzimes and pro-inflammatory 
cytokines
41-43
. 
- Effect on microorganisms and host defenses against infection: direct action 
on anaerobic bacteria (e.g. bactericidal for Clostridium perfringens) and 
toxins inhibition (in most aerobic and microaerophilic microrganisms); 
indirect action on the microbial capability of polymorphonucleocytes and 
macrophages (by raising or restoring normal oxygen pressure within the 
infected areas, thus enhancing the leukocyte oxidative killing), and 
enhancement of the antimicrobial activity of some antibiotics.  
- Neovascularization: angiogenesis in ischemic tissues is stimulated both by 
hyperoxia, a potent stimulus for fibroblast proliferation and collagen 
deposition (important to provide support for neovascularization), and by the 
relative hypoxia that occurs between the HBO treatments, a potent stimulus 
for angiogenesis. 
- Wound healing: due to the beneficial effects described above (fibroblast 
proliferation, angiogenesis and antimicrobial effect).  
 
 
Clinical indications of HBO 
 
Facing the increasing evidence of HBO’s benefits, the U.S. Undersea and 
Hyperbaric Medical Society (UHMS) set up a committee of university experts from a 
number of medical and surgical fields, specialists in hyperbaric or underwater medicine, 
whose task was to analyze the available literature and draw from this a report on 
accepted indications for HBO, based on effectiveness and cost-impact. The first list of 
HBO indications was published in 1977 by the UHMS in the form of a report to medical 
funders. Since then this report has been revised every 3 years
7
. 
In Europe, the European Committee for Hyperbaric Medicine (ECHM) chose to 
hold international consensus conferences, also based on Evidence Based Medicine 
(EBM) methodology. The first took place in Lille, France in 1994. At that time, it was 
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found that not many of the recommendations were supported by a high level of 
evidence according to the methodology of EBM, but they were regarded as a good 
starting point for further research and experience
7
. Since then, a number of conferences 
have taken place, the last and 9
th
 in Belgrade, Serbia in September 2012. 
Recommendations that emerge from these conferences are published every few years. 
The last recommendations concerning HBO’s clinical indications were issued during 
the 7
th
 European Consensus Conference on Hyperbaric Medicine in 2004
45
 (Annex 2). 
SSHL was one of the listed indications, with recommendation type 2 and level B of 
evidence
45
 (Annex 2). 
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OBJECTIVES 
 
As clear, irrefutable information is still lacking about the underlying etiology, 
pathophysiology and mechanisms of SSHL, and as most of the Portuguese patients with 
this entity are referred to the Undersea and Hyperbaric Medical Center (UHMC) at 
Lisbon (in accordance with the most recent guidelines of best clinical practice), we aim 
to evaluate the clinical evolution of such patients during a minimum period of 5 years, 
in an attempt of getting more information about potential clinical associations.  
 
Our primary endpoints are: 
 To evaluate the medical history of patients with SSHL treated with HBO in 
the UHMC during a minimum period of 5 years, focusing in the inset of new 
pathologies (particularly cardio and cerebrovascular, neoplastic, auto-
immune, endocrine and/or infectious diseases). 
 Subsequently, to identify potential risk factors or clinical associations related 
to the occurrence of SSHL. 
 
Our secondary endpoints are:  
 To characterize the pool of patients treated with HBO in the UHMC for 
SSHL, regarding demographic data, past medical history and characteristics 
of the hearing loss. 
 To evaluate clinical evolution of those patients, vis-à-vis their answer to 
HBO (in terms of recovery). 
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MATERIALS AND METHODS 
 
This is the project of a retrospective observational study, based on patients 
treated with HBO in the UHMC for SSHL at least five years ago. This project – and the 
respective informed consent form – was submitted to and approved by the Ethical 
Committee of the Portuguese Navy Hospital (in which UHMC was located). It is not a 
study but a preliminary test instead, since the calculated sample is vast (in accordance to 
the relatively low incidence of SSHL), and human resource at the UHMC is currently 
scarce. This “pretest” comprises ten subjects whose medical charts were selected among 
the target population without any randomized or blinded procedure, in a reason of 2 
charts per year. It was performed not to collect sound scientific data, but to anticipate 
eventual difficulties and estimate the logistics and materials required to conduct the 
planned study. 
In an attempt to gather maximum information with minimum bias, the target 
population is the one treated in the UHMC between January 1, 2000 and December 31, 
2007. The reason why more ancient patients cannot be included in this study group is 
related to the lack of exams in older medical charts, necessary to attest SSHL according 
to NIDCD
1
.  
A control group is also necessary: patients’ spouse/partner or close family 
member/friend that live currently with the patient and at least since the occurrence of 
SSHL. This control group is an attempt to certify that any potential risk factor or 
clinical association identified during this study is in fact related to SSHL (with a 
statistically significant difference from the control group). The criteria to choose the 
control group are based on the inclusion of persons as much similar as possible to those 
from the study group, regarding confounding variables such as age, sex, social habits, 
alimentation, exercise and hobbies – habitually difficult to match among the regular 
patients of the UHMC.  
Information will be collected by two means: a) review of medical charts of the 
study group at the UHMC; b) confidential questionnaires applied telephonically by the 
principal investigator and its medical staff to the study and control groups:  
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 The review of the medical charts aims to collect information concerning 
demographic data, past medical history and characteristics of the hearing loss 
– and, whenever registered, results of HBO therapy (Annex 3). 
 The questionnaires focus past and present medical history and social habits 
of the study and control groups, with additional information concerning the 
results of HBO therapy in the study group (Annex 3 and 4). Most of the 
questions are closed, in order to simplify, standardize and speed up the 
answers. 
 Confidentiality will be granted through the investigator’s team, all medical 
staff, committed to patients’ confidentiality. 
 Informed consent forms will previously be sent by mail to the eligible 
subjects (2 per subject – one for the patient and the other for his/her partner) 
with an anticipation of one month before the scheduled start of the study, 
accompanied of a prepaid envelope, in order to guarantee subjects’ full 
understanding and free will to participate in this study (Annex 5 and 6).  
Inclusion criteria comprise: 1) the presence in each chart of an initial 
audiometric exam that demonstrates sensorineural hearing loss of at least 30dB 
affecting at least 3 consecutive frequencies (as opposed to the contralateral ear’s 
thresholds), and clinical reference to the sudden occurrence of this hearing loss; 2) valid 
telephone number; 3) presence in each chart of a final audiogram. 
Exclusion criteria include: 1) subjects with invalid, deactivated or non-
responding phone numbers; 2) subjects without current spouse/partner/family 
member/friend or in cases where they weren’t living with the patient at the time of the 
occurrence of SSHL; 3) subjects who don’t send back the signed informed consent form 
both for him/her and his/her partner. 
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RESULTS  
 
Eight hundred and seventy eight patients were treated during the defined period 
of time of our study. We decided to apply our preliminary test to ten patients (and ten 
respective control subjects).  
Seventeen medical charts were consulted before the 10 patients were selected: 
some lacked initial audiogram (1), others lacked valid telephone numbers (3). From 
those who were selected, 2 didn’t answer the phone despite several attempts at different 
days, and 1 had changed his address.  
We also experienced some problems concerning informed consent – which was 
asked telephonically to each subject after explaining our study project –, due to some 
initial suspicion and apprehensiveness regarding the calling person’s identity. Although 
rare and easily solved by presenting confidential data regarding the subjects themselves 
(addresses, date of birth, occurrence of SSHL) obtained through their medical charts, it 
may be a serious issue and may compromise the subjects’ collaboration. We believe, 
however, that this won’t be a problem if written informed consent forms will be sent 
prior to phone calls, as originally planned in our study.  
Considering the interviews, no difficulties were experienced regarding people’s 
availability to answer questions. Most of them were really empathetic and willing to 
participate in the study, especially those who hadn’t respond to treatment for SSHL.  
The average time of each phone call was 8,30 minutes and the subjects had to be 
contacted an average of 1,5 times (in different days and at different times) to answer the 
phone and/or to be at home. This happened because most of the selected subjects had 
given their home numbers instead of their cell phone numbers, which made it much 
more difficult to contact them. The best period of time to contact such subjects was 
found to be from 6 to 9pm, after working hours – that also raised the odds to find their 
eventual spouse/partner/family member/close friend at home. In the other hand, people 
who had given their cell phone numbers and were more easily reached in working 
hours, had the inconvenient to be rarely with their partners during such hours and had to 
be contacted again during the same period of time than the other subjects. 
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The participating subjects are demographically characterized in tables 1 and 2, 
which also demonstrate past and current medical history, related to the occurrence of 
SSHL. In order to guarantee subjects’ confidentiality, we attributed a number (from 1 to 
10) to each subject from the control and study groups, and grouped them in accordance 
to patients’ recovery from SSHL after HBO therapy:  
 Patients 1-3 (and respective controls): complete recovery (pale orange) 
 Patients 4-6 (and respective controls):  partial recovery (mild orange) 
 Patients 7-10 (and respective controls):  no recovery (orange) 
All subjects from the control group are spouses, except for subjects 5 and 6, who 
are brother and sister of patients 5 and 6, respectively. 
 
 Table 1. Control Group 
 Sex Age at partner’s 
SSHL diagnosis 
Mean time after 
partner’s SSHL 
Past medical history Current medical history 
Subject 1 Male 28 12 0 0 
Subject 2 Female 42 13 0 0 
Subject 3 Male 42 11 0 0 
Subject 4 Male 52 9 Chronic otitis media 0 
Subject 5 Male 28 12 0 0 
Subject 6 Female 20 8 0 0 
Subject 7 Male 50 10 Dyslipidemia (former) dyslipidemia  
Subject 8 Female 47 13 0 Dyslipidemia 
Subject 9 Female 33 10 0 0 
Subject 10 Male 55 11 0 Dyslipidemia, 
hypertension 
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Table 2. Study Group 
 Sex Age at SSHL 
diagnosis 
Mean time after 
SSHL 
Past medical history Current medical history 
Patient 1 Female 27 12 Bilateral otosclerosis, 
slight smocking habits 
(8/day), scuba dive 
0 
Patient 2 Male 46 13 0 0 
Patient 3 Female 43 11 Migraine, “natural” 
(unknown) meds to 
lose weight 
(former) migraine 
Patient 4 Female 53 9 0 0 
Patient 5 Male 25 12 0 0 
Patient 6 Male 22 8 0 0 
Patient 7 Female 48 10 0 Dyslipidemia  
Patient 8 Male 50 13 0 Dyslipidemia 
Patient 9 Male 30 10 0 Hypertension, auto-
immune diseases: 
dermatomiositis (3y), 
miastenia gravis (8y) 
Patient 10 Female 49 11 Non-medicated 
hypertension, slight 
smocking habits 
(3/day) 
Hypertension  
 
The two groups were quite similar in terms of age and sex distribution. The 
mean ages at onset of SSHL were 39,7 years old (y.o.) for the control group and 39,3 
y.o. for the study group. There was also a similarity in terms of past medical history 
(more specifically cardiovascular diseases), with 1 patient in the control group with 
dyslipidemia and 1 patient in the study group with new, undiagnosed and non-
medicated hypertension. Nevertheless, subjects from the study group showed more 
frequently slight smocking habits (2 versus none in the control group) and some 
potential risk factors to SSHL: scuba dive before SSHL (patient 1), unknown and 
uncontrolled meds to lose weight (patient 3). 
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In terms of current diseases (diagnosed after SSHL onset), we can verify that 
cardiovascular diseases appeared in both groups in a similar way (two cases of 
dyslipidemia and 1 of hypertension in the control group versus 2 cases of dyslipidemia 
and 2 of hypertension in the study group). The major difference encountered was the 
onset of 2 rare auto-immune diseases (dermatomiositis – only 3 years after SSHL – and 
miastenia gravis) in patient 9, which was not reported in the control group. 
 
 Concerning SSHL, subjects from the “no recovery” group were older (mean age 
of 44,3 y.o.) than those from the “complete” (38,7 y.o) and “partial” (33,3 y.o.) 
recovery groups. They also had a predominant plain audiometric curve (much more 
frequent than in the other groups) and high absolute thresholds of hearing (ATH > 
80dB), suggestive of severe hearing loss – table 3.  
 
Table 3 – SSHL characteristics in the study group 
 Start 
HBO 
(days) 
Number 
of HBO 
sessions 
Mean absolute 
threshold of 
hearing (ATH) 
Audiometric pattern Accompanying 
symptoms 
Recovery from 
accompanying 
symptoms 
Patient 1 6 10 95 Low frequency loss Posture instability  
+ tinnitus 
Complete 
Patient 2 4 10 70 Plain curve 0 --- 
Patient 3 5 1 45 Low frequency loss Vertigo + tinnitus Complete 
Patient 4 5 20 70 Plain curve Tinnitus Partial 
Patient 5 10 15 75 High frequency loss Tinnitus Partial 
Patient 6 12 20 110 Low frequency loss Vertigo Complete 
Patient 7 5 20 70 Low frequency loss Vertigo + tinnitus Vertigo-partial; 
Tinnitus-0 
Patient 8 2 20 100 Plain curve Vertigo + tinnitus Vertigo-partial; 
Tinnitus-0 
Patient 9 20 20 95 Plain curve 0 --- 
Patient 10 7 15 65 Plain curve Vertigo + tinnitus Vertigo-
complete; 
Tinnitus-partial 
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The average time between SSHL onset and 1
st
 appointment at the UHMC was 
7,6 days, with higher scores in the “partial” and “no recovery” groups (means of 9 and 
8,5 days respectively). All of them had unilateral SSHL. Accompanying symptoms 
were more frequent and more severe in the “no recovery” group and had a worse 
outcome after HBO therapy despite higher number of sessions (average of 18 in the 
“partial” and “no recovery” groups versus 10 in the “complete recovery” group). No 
differences were identified among patients’ results of further exams 
(electrocardiograms, chest x-rays, blood tests, computed tomographic – CT – scans or 
magnetic resonance imaging – MRI), which were all normal. 
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DISCUSSION 
 
First of all, it must be remembered that being a preliminary study, results cannot 
be interpreted rigorously or accurately, once the sample of subjects is too small to allow 
any inference. However, some observations may be pointed out:  
 Subjects from the control and study groups appeared to be similar and 
matched in terms of sex and age distribution. 
 Cardiovascular diseases appeared in both groups in a similar way, but 
patient 9 developed 2 rare auto-immune diseases in a short period of time 
after SSHL, which was unnoticed in the control group. 
 Negative prognostic factors were observed in the “no recovery” group 
(older age, severe hearing loss, plain audiometric pattern, accompanying 
vertigo) in accordance to published data. 
That being said, discussion will focus problems and difficulties faced or 
anticipated during the preliminary test, which may influence the achievement of the 
study test. 
The first difficulty to appear was the selection of subjects with valid phone 
numbers, especially among the earlier patients. Some of the times phone numbers were 
not written on the medical charts, in others they were incorrect or invalid.  
Review of medical charts was also not so easy, since they are hand wrote, with 
different calligraphies, more or less legible accordingly to the physician who wrote 
them. Data is also missing from some charts, mostly co-morbidities or past medical 
history, treatments experienced before HBO therapy, and associated symptoms and their 
evolution (improvement or not). Such lack of information may be explained by the 
multitude of specialists (internists, otolaryngologists, ophthalmologists, dermatologists 
and pulmonologists) that work (or worked since the year 2000) at the UHMC, receiving 
all patients at their consultations including those with SSHL. Some may have not be so 
aware of the importance of patients’ previous treatments or accompanying symptoms, 
especially because that wasn’t really under discussion back then. In all charts reviewed, 
none lacked the initial audiogram and none was misinterpreted as SSHL. 
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Once the subjects were selected and the telephonic contacts begun, other 
obstacles arose. The most difficult to overcome was to get the subjects at the phone – 
either because they didn’t answer or because they weren’t at home. Another important 
obstacle was related to the absence of an eventual spouse/partner/family member – in 
cases of inexistence, patients were withdraw from the pretest; in cases of simple 
absence, further contact had to be established later. This difficulty was more or less 
easily overcome by contacting the selected subjects later during the day, from 6 to 9 pm, 
as described above. 
Other anticipated problems were possible bias in this study. The selection bias 
may be a concern, since it is probable that earlier patients will be loss to follow-up due 
to lack of information in their charts, invalid or non-responding phone numbers, and 
death – of the patient himself or his spouse/partner. This last point is particularly true 
not only with earlier patients but also with older patients at the time of onset of SSHL.  
Another important bias that was considered was confounding bias – this will 
hopefully be reduced through our defined control group (which is expected to be a good 
match for the study group) and stratified analysis of results. Accurate sample size 
calculation, based on the incidence of the disease and its recovery rates, on the alpha 
error and the study power, may also be an important point to reduce confounding bias. 
Information bias is also of great concern in this study, especially because it is a 
retrospective study that is based on subjects’ memory (which may lead to recall bias). It 
is also based on incomplete, illegible medical files (written by different physicians, at 
different times of assessment) and telephonic questionnaires (that raise the possibility of 
wrong, incomplete or misleading answers from subjects who do not wish to fully 
expose their medical conditions). Strategies to reduce this bias may be to confront 
information given by patients and partners regarding each other medical conditions and 
time of onset (before or after SSHL), as well as reviewing with each subject all diseases 
specified in the questionnaire, even if they are globally denied at first. 
Assessment bias is another possibility, once this retrospective study is not blind 
and the investigator and his team will always be aware during the phone calls whether 
they are interacting with subjects from the study or control group. A tendency to spend 
more time with the patient trying to identify any recent medical condition opposed to 
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less vigorous attempt to ascertain the partner’s diseases must be controlled and avoided 
by rigorous staff formation and questionnaire application.  
Finally, a frequently anticipated problem is the total cost of the study. In this 
case, costs don’t represent a big concern, since this study is planned to be conducted by 
medical staff that ordinarily works or has contact to the selected patients and their 
respective charts at the UHMC. Extra costs, related to phone calls and papers, ink and 
envelopes needed to send the informed consent forms to the selected subjects don’t 
seem to constitute a major problem, since: a) the required information can be obtained 
by phone rather quickly as demonstrated in the preliminary study (at no costs with 
national home numbers and reduced costs for cell phone numbers), and b) all subjects 
live in Portugal, which significantly reduces mail prices.  
In fact, the major problem anticipated is the time and the number of persons 
needed to fulfill the questionnaires, since it relies, as we have observed during the 
preliminary study, on a reduced daily schedule (from 6pm to 9pm – after subjects and 
medical staff’s working hours) in order to raise chances of successful interviews. One 
possible solution may be to delegate this job on medical students, eventually interested 
by clinical investigation and, particularly by this theme and study project. Medical 
students may be a good option, since they have more free time and are naturally 
enthusiastic and driven at this point of their career, even if no (or few) financial 
compensation can be offered, as long as their work will be recognized through 
publication. More importantly, they are used to medical terms, confidentiality issues 
and to the delicate physician-patient relation, which may turn them into valuable allies 
with precise and close supervision. 
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CONCLUSION 
 
 SSHL is a relatively common pathology that carries substantial personal, 
medical and professional burden to patients’ lives. Besides its impact on quality of life, 
it is responsible for absenteeism and impaired professional opportunities (persons with 
earing disabilities are enabled to pursue military, aviation, aeronautics and musical 
careers, to name a few). Heavy medical costs are also a reality, mainly related to 
inpatient treatments (applied in some medical facilities before current guidelines) and 
HBO therapy (prices of full treatment – 10 to 15 sessions – are calculated to be around 
760 to 1110 euros/patient). Adverse effects of some proposed therapies (including 
corticosteroids) also bring extra costs that are sometimes hard to handle. 
 HBO therapy, as a primary or adjunct treatment, appears to be effective, with 
fewer adverse effects than corticotherapy, but data is missing concerning real 
effectiveness and mechanisms of action. Likewise, SSHL is still a poorly understood 
entity with unclear etiopathology. Efforts must be made to clarify pathophysiology and 
identify causative agents, in order to ameliorate current treatments and prognosis. 
 As it is believed that SSHL is not a disease by itself but rather a symptom of an 
underlying disease, we believe that it is essential to take a step back and look closer to 
patients who had SSHL years ago. This epidemiologic study is therefore important, 
since it is intended to ascertain what medical conditions have arose since then and what 
clinical associations may be inferred. 
This is not the first epidemiologic study in this area (a few were made focusing 
specific cardiovascular diseases
46
 and infectious diseases – with vague conclusions) but 
it is the more comprehensive and will hopefully generate sound scientific knowledge 
concerning pathophysiology and mechanism of disease of SSHL. If the results point 
toward an eventual clinical association, it may open new perspectives and serve as a 
trampoline to other, more focused, studies. The ultimate goal is to contribute to the 
discovery and/or improvement of adequate treatments, aiming to increase patients’ 
quality of life. 
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Annex 1 
Sudden Sensorineural Hearing Loss 
 
1. Tinnitus Handicap Inventory 
 
The THI is a 25-item questionnaire developed to assess the severity of the 
patients’ perceived tinnitus handicap, with items that are grouped into three subscales: 
functional, emotional and catastrophic responses.  The functional subscale items reflect 
the effect of tinnitus on mental, social, occupational and physical functioning. The 
emotional subscale items probe the individual’s emotional reactions to the tinnitus and 
the catastrophic response items address whether tinnitus makes the respondent feel 
desperate, trapped, hopeless or out of control.   
A “yes” response is given 4 points, a “sometimes” response is given 2 points and 
a “no” response is given 0 points. The questionnaire yields scores for each subscale and 
a total score that ranges from 0 and 100, with high scores indicating a greater handicap: 
0–16  Slight or no handicap (Grade 1) 
Only heard in a quiet environment 
18–36 Mild handicap (Grade 2) 
Easily masked by environmental sounds and easily forgotten with activities 
38–56  Moderate handicap (Grade 3) 
Noticed in presence of background noise, although daily activities can still be 
performed 
58–76  Severe handicap (Grade 4) 
Almost always heard, leads to disturbed sleep patterns and can interfere with 
daily activities. 
>78  Catastrophic handicap (Grade 5) 
Always heard, disturbs sleep patterns and causes difficulty with any activities. 
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2. Dizziness Handicap Inventory 
 
The DHI is a 25-item questionnaire developed to assess the severity of the 
patients’ perceived dizziness handicap, with items that are grouped into three subscales: 
functional, emotional and physical responses.  The functional subscale items reflect the 
effect of dizziness on mental, social and occupational functioning. The emotional and 
physical subscale items probe the individual’s emotional and physical reactions to the 
dizziness, respectively.   
A “yes” response is given 4 points, a “sometimes” response is given 2 points and 
a “no” response is given 0 points. The questionnaire yields scores for each subscale and 
a total score that ranges from 0 and 100, with high scores indicating a greater handicap: 
 
0–14   Slight or no handicap  
16–34   Mild handicap  
36–52   Moderate handicap  
> 54   Severe handicap  
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Annex 2 
Hyperbaric Oxygen 
 
1. Multiplace hyperbaric chamber  
 
 
The internal atmosphere is room air compressed up to 2,5 ATA. Patients inside 
the chamber bread compressed air, accruing a nitrogen load in their soft tissues similar 
to scuba divers. As such, they need to decompress to avoid decompression sickness – 
that is performed rigorously according to Navy tables of recompression. Hyperbaric 
oxygen is administered in periods of time via face mask; hood or endotracheal tube. 
 
 
 
The advantage of such chamber is that the patients can be attended during the 
treatment. A major disadvantage is the high costs of support. 
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2. Gas laws 
2.1. Dalton’s law 
“The total pressure exerted by a gaseous mixture is equal to the sum of 
the pressures that would be exerted by the gases if they alone were 
present and occupied the total volume”. 
 
Ptot = p1 + p2 + … + pn 
 
where: p1,p2,…,pn represent the partial pressures of each component. 
 
It allows calculating the partial pressure of each gas as follows: 
“The partial pressure of a gas (p1) equals the product of total pressure of 
the gaseous mixture (Ptot) and the fraction of the gas (F1)”. 
 
p1 = Ptot x F1 
 
where: F1 is defined as a part of 1; i.e. in air FO2 is 0,21.. 
 
2.2. Henry’s law 
“The mass of a gas (C) that dissolves in a defined volume of liquid is 
directly proportional to the pressure of the gas (P) (provided the gas 
does not react with the solvent)”. 
 
α x (p / C) = const, for T = const. 
 
where: p = partial pressure of the gas above the liquid; C = concentration 
of the gas in the liquid; α = Bunsen’s solubility coefficient (specific for 
gases and liquids); T = temperature. 
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2.3. Fick’s law of diffusion  
 
Rate of diffusion = (K x A x ΔP) / D 
 
where: K = constant; A = surface area over which diffusion is taking 
place; ΔP = difference of gas partial pressure on both sides of the 
membrane; D = distance over which diffusion takes place, i.e. membrane 
tickness. 
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3. Physiological effects of HBO 
3.1. Increased fraction of O2 in circulating blood during HBO at different 
levels of pressure in accordance with Dalton’s and Henry’s laws.  
 
ATAs 1 1 2 3 
FiO2 0,21 1 1 1 
Alveolar oxygen 
pressure (PAO2, mmHg) 
100 673 1433 2193 
Hb(O2)4 (vol.%) 19,7 20,1 20,1 20,1 
O2/Plasma (mL/100mL) 0,285 1,88 3,0 6 
 
Hb(O2)4 – hemoglobin’s oxygen saturation in circulating blood; O2/Plasma – dissolved fraction 
of oxygen in the plasma. 
 
3.2. Correction of tissue hypoxia under HBO, in accordance with Fick’s law. 
 
ATA 1 3 
Fi O2 0,21 1 
Alveolar PO2 (mmHg) 100 2193 
Hb(O2) 4 (vol.%) 19,7 20,1 
Plasma O2 (vol.%) 0,285 6 
Arterial PO2 (mmHg) 95-100 2052-2193 
Tissue PO2 (mmHg) 40 402,8 
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4. ECHM Recommendations (7th European Consensus Conference on 
Hyperbaric Medicine, Lille 2004) 
The Jury issued its recommendations using a 3 grade scale according to the strength 
each recommendation had been evaluated:   
- Type 1:  Strongly Recommended. The implementation of the recommendation is 
considered of critical importance for final outcome of the patient/quality of 
practice/future specific knowledge.  
- Type 2:  Recommended. The implementation of the recommendation will 
positively affect final outcome of the patient/quality of practice/future specific 
knowledge.  
- Type 3:  Optional. The implementation of the recommendation is considered to 
be an option.   
 Such recommendations were supported by the following level of evidence (issue 
for clinical research): 
- Level A: At least 2 concordant, large, double-blind, controlled randomized 
studies with no or little methodological bias (type 1 recommendation). 
- Level B: Double-blind controlled, randomized studies but with methodological 
flaws; studies with only small samples, or one study only (type 2 
recommendation). 
- Level C: Consensus opinion of experts (type 3 recommendation). 
- Level D: Only uncontrolled studies with no consensus opinion of experts. 
- Level E: No evidence of beneficial action, or methodological or interpretation 
bias precluding any conclusion. 
- Level F: procedure not indicated by existing evidence. 
Sudden Sensorineural Hearing Loss – evaluation of co-morbidities and potential clinical associations 
 48 
 
 
Sudden Sensorineural Hearing Loss – evaluation of co-morbidities and potential clinical associations 
 49 
 
 
 
Sudden Sensorineural Hearing Loss – evaluation of co-morbidities and potential clinical associations 
 50 
Annex 3 
 
 
First questionnaire (study group) 
 
 Yes No 
Identification 
Age  
Sex  
Profession  
Provenience  
Past Medical History (date of occurence/diagnosis) 
Smoking habits (cigarettes/day)   
Ethanolic habits (g/day)   
Drugs (cocaine, heroin, methadone)   
Cardiovascular diseases 
Arterial hypertension (HTN) 
  
Dyslipidemia   
Diabetes mellitus (DM)   
Stroke / transient ischemic attack (TIA)   
Acute coronary syndrome (ACS) / ischemic cardiomyopathy / coronary 
artery disease (CAD) 
  
Dysrhythmia (atrial  fibrillation – AF –, long QT syndrome)    
Renal pathology   
Obstructive sleep apnea syndrome (OSAS)   
Autoimmune / rheumatologic diseases 
Systemic lupus erythematosus (SLE) / rheumatoid arthritis (RA) 
  
Ankylosing spondylitis (AS) / Sjogren    
Polyarteritis nodosa / Wegener’s granulomatosis   
Sarcoidosis / Beçhet    
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Hashimoto’s thyroiditis / inflammatory bowel disease (IBD)   
Multiple sclerosis (MS)   
Neoplastic diseases  
Vestibular schwanomma  / other cerebellopontine angle tumors 
  
Neurofibromatosis (type 2 – central nervous system)   
Other brain tumors   
Brain metastases / carcinomatous meningitis   
Traumatic brain injury (TBI) / Barotrauma   
Infections 
Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency 
Syndrome (AIDS)   
  
Parotiditis / measles / rubella    
Cytomegalovirus (CMV) / Epstein-Barr Virus (EBV)   
Hepatitis B Virus (HBV) / HSV (herpes simplex virus)   
Tuberculosis (TB) / Syphilis (2
ary
/3
ary
)   
Tropical infections (Chagas’ disease, Legionella, Lyme, Malaria)   
Middle ear infections / labyrinthitis / vestibular neuronitis    
Meningitis   
Endocrine diseases 
Hypo / Hyperthyroidism   
  
DM    
Adrenal pathology   
Hyperviscosity 
Sickle cell disease (SCD) 
  
Antiphospholipids syndrome (APS)   
Polycythemia vera (PV) / Essential thrombocytosis (ET)   
Leukemia / lymphoma   
Waldenstrom’s macroglobulinemia / Multiple myeloma (MM)   
Medication 
Chemotherapy (cisplatin, carboplatin)  
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Aminoglycosides (gentamycin, neomycin)   
Vancomycin   
Tuberculostatics (streptomycin)   
Antimalarials (primaquine, quinine)   
Loop diuretics (furosemide)   
Acetylsalicylic acid (ASA)   
Phosphodiesterase type 5 inhibitors (PDE5-inhibitors: sildenafil, 
vardenafil, tadalafil)  
  
Ribavarin / Pegylated interpheron alfa-2a (PEG-IFN)   
SSHL 
Date of occurrence / diagnosis  
Laterality   
Accompanying symptoms   
Vertigo 
  
Tinnitus   
Precedents (30 days before SSHL) 
Infectious diseases (upper or lower respiratory tract infections +/- acute 
otitis media, conjunctivitis, meningitis, exacerbated chronic otitis 
media, digestive tract or cutaneous infection; tuberculosis, rubella, 
mononucleosis, parotiditis, herpes, syphilis) 
  
Brain ischemia (strong headache, syncope, stroke / TIA); asthma crisis; 
epilepsy crisis 
  
Head trauma/TBI, intracranial hypertension (vomits, blurry vision)   
Barotrauma / acoustic trauma (diving, snorkeling, explosion, 
aggression, sport / traffic accident) 
  
Recent surgery under general anesthesia   
Meds, drugs 
 
  
New-onset of pathology   
Audiometric exam 
Severity 
  
Pattern   
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Further exams 
Blood tests (abnormal results?) 
  
Electrocardiogram (abnormal rhythm?)   
Chest x-ray (pulmonary tuberculosis?)   
Others (CT scan / MRI changes?)   
Medical treatment 
Corticosteroids 
  
Antivirals   
Vasodilatadors   
Others   
HBO therapy 
Date of start 
 
Date of completion  
Number of sessions  
Clinical evolution 
Complete / Partial Recovery  
  
Hearing loss?    
Tinnitus?   
Vertigo?   
No recovery   
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Annex 4 
Second questionnaire (study and control groups) 
 
 Yes No 
Identification 
Age  
Sex  
Profession  
Provenience  
Past Medical History (date of occurence/diagnosis) 
Smoking habits (cigarettes/day)   
Ethanolic habits (g/day)   
Drugs (cocaine, heroin, methadone)   
Cardiovascular diseases  
HTN, dyslipidemia, DM, stroke / TIA, ACS / ischemic 
cardiomyopathy / CAD, dysrhythmia (AF, long QT syndrome), 
renal pathology, OSAS  
  
Autoimmune / rheumatologic diseases  
SLE, RA, AS, Sjogren, Polyarteritis nodosa, Wegener’s 
granulomatosis, sarcoidosis, MS, Hashimoto’s thyroiditis, Behçet, 
DII 
  
Neoplastic diseases (with or without brain metastases)   
TBI / Barotrauma   
Infections 
HIV/AIDS, CMV, EBV, HBV, HSV; parotiditis, measles, rubella, 
CMV 
  
TB, syphilis; tropical infections (Chagas’, Lyme’s, Malaria);    
Menigitis; middle / internal ear infections   
Endocrine diseases 
Hypo/hypertiroidism, DM, adrenal pathology 
  
Hyperviscosity 
SCD, APS, PV, ET, leukemia/lymphoma, Waldenstrom’s 
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macroglobulinemia, MM 
Other diseases 
Hepatic disease (hepatic failure, cirrhosis, others) 
  
Pulmonary disease (asthma, chronic obstructive pulmonary disease 
– COPD –, TB, pulmonary hypertension) 
  
Meds 
Chemotherapy, amynoglycosides, vancomycin, tuberculostatics, 
antimalarials, loop diuretics, ASA, PDE5 inhibitors, ribavarin / 
PEG-IFN 
  
Follow-up (new onset of pathology) 
Otologic diseases 
Recurrent SSHL (if yes, report again to the 1
st
 questionnaire – 
SSHL) 
  
Meniere’s disease   
Enlarged vestibular aqueduct syndrome/other congenital internal 
ear malformation 
  
Cardiovascular diseases 
Stroke / TIA (date of occurence, brain area damaged, number of 
episodes?) 
  
Cerebrospinal fluid leak (cranial hypothension)   
Autoimmune / rheumatologic diseases 
Behçet, Sjogren, IBD 
  
SLE, RA, Cogan’s syndrome, juvenile rheumatic arthritis   
Polyarteritis nodosa, Wegener’s granulomatosis, sarcoidis   
MS, Hashimoto’s thyroiditis   
Endocrine diseases 
Hypothyroidism 
  
Neoplastic diseases 
Vestibular schwanomma  / other cerebellopontine angle tumors 
  
Brain metastases / carcinomatous meningitis    
Neurofibromatosis (type 2 – central nervous system)   
Leukemia / lymphoma, MM, Waldenstrom’s macroglobulinemia, 
PV, ET 
  
Others   
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Annex 5 
Informed Consent Form 
Sudden Sensorineural Hearing Loss – evaluation of co-morbidities and potential 
clinical associations  
 
Sudden sensorineural hearing loss (SSHL) is characterized by a sudden, 
idiopathic loss of hearing of at least 30 decibels (dB) affecting at least 3 consecutive 
frequencies. It preferentially affects working adults in the 40ths, with no sex 
preponderance. Though its relatively low incidence (5-20/100.000 people/year), SSHL 
plays an important role in today’s medicine due to its huge impact on quality of life and 
its unknown pathophysiology, with subsequent controversial (and frequently 
ineffective) treatment. 
Clinically, SSHL is characterized by sudden hearing loss, generally unilateral 
and frequently associated to aural fullness, tinnitus and vertigo. Spontaneous recovery is 
reported in as much as 60% of the patients, but it may take up to 6 months to occur. The 
remaining 40% of the patients experience variable responses to current treatments, with 
estimated rates of total and partial recovery rounding around 18 to 25% and 40 to 60%, 
respectively.  
Possible causes of SSHL include infectious, circulatory, neoplastic, traumatic, 
metabolic, neurologic, immunologic, toxic and unidentified cochlear diseases. 
Nevertheless, its etiology remains unknown in the vast majority of the cases (more than 
80%), giving rise to controversial choices of adequate treatment. Available therapies 
range from corticosteroids to antivirals, vasodilators, antiaggregants, anticoagulants, 
vitamins and hyperbaric oxygen, with different levels of (estimated) effectiveness and 
adverse effects.  
Oral corticosteroid therapy is one of the few modalities that have proved to be 
effective in randomized controlled studies, but it is related to significant systemic 
adverse effects. Hyperbaric oxygen as a primary, adjunct or secondary therapy appears 
to be a valid choice, especially where systemic steroid are contraindicated or in patients 
who failed to respond to such drugs, with the benefit of less adverse effects. 
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Nonetheless, its real effectiveness remains unclear due to the lack of randomized 
controlled studies and the relatively high rate of spontaneous recovery. 
Given the lack of data concerning SSHL’s etiology and mechanisms of disease, 
we intend to evaluate clinical evolution of patients with SSHL treated with hyperbaric 
oxygen in the Underwater and Hyperbaric Medical Center at Lisbon from 2000 to 2005, 
during a minimum period of 5 years, in an attempt to identify eventual risk factors or 
clinical associations to SSHL. 
If you belong to this group of patients, you and your spouse/partner/close family 
member will be asked to answer a clinical questionnaire performed telephonically. It 
will also be asked your permission to access and review your medical file from the 
Underwater and Hyperbaric Medical Center. 
 
The participation in this study requires your consent. In order to help you to 
decide, this written information was elaborated and attached to the study’s protocol. 
Any questions you might have will be answered by the principal investigator, Dr. Sonia 
Pereira, physician at the Underwater and Hyperbaric Medical Center (contact number: 
+351 218840821). 
 
 
Underwater and Hyperbaric Medical Center – Lisbon, January 2013 
 
 
  
Sonia Pereira, MD 
Otolaryngology resident  
(Ordem dos Médicos nº 46181) 
 
 
Name __________________________________________________________ 
Local___________________________________ Date____________________ 
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Annex 6 
Informed Consent Form in Portuguese (Original) 
Avaliação de co-morbilidades em doentes com surdez súbita e sua eventual relação 
nosológica 
 
 
A surdez súbita, caracterizada por uma perda súbita de audição superior ou 
igual a 30 dB no mínimo de três frequências de audição, afecta preferencialmente 
adultos na década de 40, independentemente do sexo. Apesar de não ser uma patologia 
muito frequente (5-20/100.000 pessoas num ano), reveste-se de particular importância 
pelo impacto significativo na qualidade de vida dos doentes e pela ausência da 
identificação de causa na grande maioria dos casos (com consequências óbvias na 
escolha do tratamento mais adequado). 
As manifestações clínicas caracterizam-se por uma surdez de instalação súbita, 
muitas vezes ao acordar, que se associa frequentemente a sensação de plenitude 
auricular, acufenos e vertigem. A recuperação espontânea pode ir ter até aos 60%, mas 
prolongar-se até 6 meses após o aparecimento da doença. Os 40% restantes dos 
doentes obtêm respostas variáveis com os tratamentos actuais, com resultados a rondar 
entre os 40 a 60% de recuperação parcial e os 18-25% de cura. 
A escolha dos tratamentos mantém-se controversa, por desconhecimento 
etiológico da doença, incluindo-se corticóides, anti-virais, vasodilatadores, expansores 
de plasma, anti-agregantes e anti-coagulantes, vitaminas e sais minerais ou 
oxigenoterapia hiperbárica, entre as modalidades de tratamento.  
Apesar de não existir consenso absoluto entre especialistas, estudos recentes 
apontam para um maior efeito dos corticóides e da oxigenoterapia hiperbárica, desde 
que iniciados nos primeiros quinze dias de aparecimento da doença (coincidente com o 
início da recuperação espontânea segundo a história natural da doença, o que dificulta 
a avaliação da real eficácia da terapêutica instituída). 
Atendendo à inexistência actual de dados esclarecedores da causa e dos 
mecanismos desta doença, pretende-se avaliar a evolução dos doentes tratados por este 
motivo no Centro de Medicina Subaquática e Hiperbárica entre o ano de 2000 e 2002 
após um período mínimo de cinco anos, com identificação de eventuais factores de 
risco ou associações clínicas relacionadas com a surdez súbita.  
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Se pertencer a este grupo de doentes, será pedida a sua colaboração e a do seu 
conjugue/parceiro(a) ou equiparado na resposta a um questionário clínico por via 
telefónica. Será também pedida a sua autorização para a consulta do seu processo 
médico existente no Centro de Medicina Subaquática e Hiperbárica. 
  
A participação neste estudo necessita da sua autorização. Para o ajudar a 
decidir, foi elaborada esta informação escrita, assim como foi anexado o protocolo do 
estudo a efectuar, mas serão respondidas todas as eventuais questões ou dúvidas 
persistentes pela médica investigadora, pertencente ao quadro clínico do Centro de 
Medicina Subaquática e Hiperbárica (contacto telefónico: 218840821). 
 
Centro de Medicina Subaquática e Hiperbárica, 
 
 
 
 
 
 
Dra. Sonia Lopes Pereira 
Interna de Otorrinolaringologia 
Nº da Ordem dos Médicos: 46181 
 
Nome __________________________________________________________ 
Local___________________________________ Data____________________ 
 
